Rovalpituzumab tesirine

Drug Profile

Rovalpituzumab tesirine

Alternative Names: Rova-T; SC16LD6.5

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Stemcentrx
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DLL3 protein inhibitors; DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 02 Mar 2017 AbbVie plans a phase III trial for Small cell lung cancer (Metastatic-disease, Late-stage disease, Second-line therapy or greater) (NCT03061812)
  • 07 Feb 2017 Phase-III clinical trials in Small cell lung cancer (Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03033511)
  • 25 Jan 2017 AbbVie plans the phase III MERU trial for Small cell lung cancer (Late stage disease, Maintenance therapy) in USA (IV) (NCT03033511)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top